OTCMKTS:MKGAF

MERCK Kommanditgesellschaft auf Aktien Stock Forecast, Price & News

$190.50
0.00 (0.00 %)
(As of 06/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$190.50
▼
$190.50
50-Day Range
$160.60
▼
$190.50
52-Week Range
$111.95
▼
$190.50
VolumeN/A
Average Volume396 shs
Market Capitalization$24.62 billion
P/E Ratio30.93
Dividend YieldN/A
Beta0.71
30 days | 90 days | 365 days | Advanced Chart
Receive MKGAF News and Ratings via Email

Sign-up to receive the latest news and ratings for MERCK Kommanditgesellschaft auf Aktien and its competitors with MarketBeat's FREE daily newsletter.


MERCK Kommanditgesellschaft auf Aktien logo

About MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat oncology, immuno-oncology, neurology, immunology, fertility, and endocrinology, as well as general medicines for diabetes, cardiovascular, thyroid, and other diseases. The company also provides life science products and services, including research, process, and applied solution. In addition, it offers specialty chemicals for semiconductor, liquid crystals, organic light-emitting diodes, effect pigments, automotive, and functional solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Novartis AG and Vera Therapeutics, Inc.; and collaboration with F-star Delta Ltd. and Artios Pharma Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. Merck KG.

Headlines

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Hits New 12-Month High at $190.50
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Hits New 12-Month High at $190.50
June 23, 2021 |  americanbankingnews.com
Financial Survey: Apellis Pharmaceuticals (NASDAQ:APLS) & MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF)
Financial Survey: Apellis Pharmaceuticals (NASDAQ:APLS) & MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF)
June 16, 2021 |  americanbankingnews.com
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Update
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Update
June 14, 2021 |  americanbankingnews.com
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Hits New 1-Year High at $190.25
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Hits New 1-Year High at $190.25
June 8, 2021 |  americanbankingnews.com
Germanys Merck in fresh investment to make bioreactor gear in France
Germany's Merck in fresh investment to make bioreactor gear in France
March 17, 2021 |  finance.yahoo.com
Gileads remdesivir to be tested with Merck KGaAs interferon vs. COVID by NIH
Gilead's remdesivir to be tested with Merck KGaA's interferon vs. COVID by NIH
August 7, 2020 |  feeds.marketwatch.com
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
March 2, 2020 |  finance.yahoo.com
Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?
Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?
January 22, 2020 |  finance.yahoo.com
Merck KGaA to reconsider selling allergy business - Bloomberg
Merck KGaA to reconsider selling allergy business - Bloomberg
January 9, 2020 |  seekingalpha.com
Versum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing Date
Versum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing Date
October 1, 2019 |  www.businesswire.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.59 out of 5 stars

Medical Sector

1446th out of 2,106 stocks

Pharmaceutical Preparations Industry

644th out of 832 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Frequently Asked Questions

What stocks does MarketBeat like better than MERCK Kommanditgesellschaft auf Aktien?

Wall Street analysts have given MERCK Kommanditgesellschaft auf Aktien a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MERCK Kommanditgesellschaft auf Aktien wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MERCK Kommanditgesellschaft auf Aktien?

MERCK Kommanditgesellschaft auf Aktien saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 255,700 shares, an increase of 72.7% from the May 13th total of 148,100 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 2,557.0 days.
View MERCK Kommanditgesellschaft auf Aktien's Short Interest.

When is MERCK Kommanditgesellschaft auf Aktien's next earnings date?

MERCK Kommanditgesellschaft auf Aktien is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for MERCK Kommanditgesellschaft auf Aktien.

How were MERCK Kommanditgesellschaft auf Aktien's earnings last quarter?

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) released its quarterly earnings data on Wednesday, May, 12th. The company reported $2.63 EPS for the quarter. The firm earned $5.58 billion during the quarter. MERCK Kommanditgesellschaft auf Aktien had a net margin of 12.89% and a trailing twelve-month return on equity of 18.12%.
View MERCK Kommanditgesellschaft auf Aktien's earnings history.

How has MERCK Kommanditgesellschaft auf Aktien's stock been impacted by Coronavirus (COVID-19)?

MERCK Kommanditgesellschaft auf Aktien's stock was trading at $111.2250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MKGAF stock has increased by 71.3% and is now trading at $190.50.
View which stocks have been most impacted by COVID-19.

Who are MERCK Kommanditgesellschaft auf Aktien's key executives?

MERCK Kommanditgesellschaft auf Aktien's management team includes the following people:
  • Ms. Belen Garijo Lopez M.D., Chair of Exec. Board & CEO (Age 61, Pay $6.1M)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 53, Pay $4.96M)
  • Dr. Kai Beckmann, CEO of Electronics & Member of the Exec. Board (Age 56, Pay $5.06M)
  • Mr. Peter Guenter, CEO of Healthcare Bus. & Member of Exec. Board (Age 59)
  • Mr. Matthias Heinzel, CEO of Life Science Sector & Member of Exec. Board (Age 54)
  • Mr. Gerhard Schmitz, Head of Global Accounting (Age 58)
  • Mr. Dirk Toepfer, Chief Information Officer
  • Mr. Constantin Fest, Head of Investor Relations (Age 44)
  • Dr. Friederike Rotsch, Group Gen. Counsel and Head of Group Legal & Compliance (Age 49)
  • Ms. Barbara Weiland, Chief Compliance Officer (Age 47)

Who are some of MERCK Kommanditgesellschaft auf Aktien's key competitors?

Some companies that are related to MERCK Kommanditgesellschaft auf Aktien include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), BeiGene (BGNE), Shiseido (SSDOY), Genmab A/S (GMAB), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP) and Alnylam Pharmaceuticals (ALNY).
View all of MKGAF's competitors.

What is MERCK Kommanditgesellschaft auf Aktien's stock symbol?

MERCK Kommanditgesellschaft auf Aktien trades on the OTCMKTS under the ticker symbol "MKGAF."

How do I buy shares of MERCK Kommanditgesellschaft auf Aktien?

Shares of MKGAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MERCK Kommanditgesellschaft auf Aktien's stock price today?

One share of MKGAF stock can currently be purchased for approximately $190.50.

How much money does MERCK Kommanditgesellschaft auf Aktien make?

MERCK Kommanditgesellschaft auf Aktien has a market capitalization of $24.62 billion and generates $20.03 billion in revenue each year.

How many employees does MERCK Kommanditgesellschaft auf Aktien have?

MERCK Kommanditgesellschaft auf Aktien employs 58,127 workers across the globe.

What is MERCK Kommanditgesellschaft auf Aktien's official website?

The official website for MERCK Kommanditgesellschaft auf Aktien is www.merckgroup.com.

Where are MERCK Kommanditgesellschaft auf Aktien's headquarters?

MERCK Kommanditgesellschaft auf Aktien is headquartered at Frankfurter Strasse 250, Darmstadt 2M, 64293.

How can I contact MERCK Kommanditgesellschaft auf Aktien?

MERCK Kommanditgesellschaft auf Aktien's mailing address is Frankfurter Strasse 250, Darmstadt 2M, 64293. The company can be reached via phone at 49-61-517-20 or via email at [email protected]


This page was last updated on 6/25/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.